Literature DB >> 32781936

Uses of pathogen detection data to estimate vaccine direct effects in case-control studies.

Joseph A Lewnard1,2,3.   

Abstract

The fact that many pathogens can be carried or shed without causing symptoms complicates the interpretation of microbiological data when diagnosing certain infectious disease syndromes. Diagnostic criteria that attribute symptoms to a pathogen which is detectable, whether it is or is not the aetiological agent of disease, may lead to outcome misclassification in epidemiological studies. Case-control studies are commonly undertaken to estimate vaccine effectiveness (VE) and present an opportunity to compare pathogen detection among individuals with and without clinically relevant symptoms. Considering this study context, we present a mathematical framework yielding simple estimators for the direct effects of vaccination on various aspects of host susceptibility. These include protection against acquisition of the pathogen of interest and protection against progression of this pathogen to disease following acquisition. We assess the impact of test sensitivity on these estimators and extend our framework to identify a 'vaccine probe' estimator for pathogen-specific aetiological fractions. We also derive biases affecting VE estimates under the test-negative design, a special case enrolling only symptomatic persons. Our results provide strategies for estimating pathogen-specific VE in the absence of a diagnostic gold standard. These approaches can inform the design and analysis of studies addressing numerous pathogens and vaccines.

Entities:  

Keywords:  causal inference; epidemiology; estimation; infectious disease; vaccine effectiveness

Year:  2020        PMID: 32781936      PMCID: PMC7482576          DOI: 10.1098/rsif.2020.0161

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  43 in total

1.  Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants.

Authors:  K Mulholland; S Hilton; R Adegbola; S Usen; A Oparaugo; C Omosigho; M Weber; A Palmer; G Schneider; K Jobe; G Lahai; S Jaffar; O Secka; K Lin; C Ethevenaux; B Greenwood
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

Review 2.  Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence.

Authors:  John S Gunn; Joanna M Marshall; Stephen Baker; Sabina Dongol; Richelle C Charles; Edward T Ryan
Journal:  Trends Microbiol       Date:  2014-07-22       Impact factor: 17.079

Review 3.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines.

Authors:  M E Halloran; C J Struchiner; I M Longini
Journal:  Am J Epidemiol       Date:  1997-11-15       Impact factor: 4.897

4.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

5.  A comparison of the test-negative and traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine effectiveness.

Authors:  Michael Haber; Benjamin A Lopman; Jacqueline E Tate; Meng Shi; Umesh D Parashar
Journal:  Vaccine       Date:  2018-07-03       Impact factor: 3.641

Review 6.  Use of vaccines as probes to define disease burden.

Authors:  Daniel R Feikin; J Anthony G Scott; Bradford D Gessner
Journal:  Lancet       Date:  2014-02-17       Impact factor: 79.321

7.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

Authors:  Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine
Journal:  Lancet       Date:  2013-05-14       Impact factor: 79.321

8.  Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Ron Dagan
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

9.  Causal inference in infectious diseases.

Authors:  M E Halloran; C J Struchiner
Journal:  Epidemiology       Date:  1995-03       Impact factor: 4.822

10.  The Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology study.

Authors:  Orin S Levine; Katherine L O'Brien; Maria Deloria-Knoll; David R Murdoch; Daniel R Feikin; Andrea N DeLuca; Amanda J Driscoll; Henry C Baggett; W Abdullah Brooks; Stephen R C Howie; Karen L Kotloff; Shabir A Madhi; Susan A Maloney; Samba Sow; Donald M Thea; J Anthony Scott
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

View more
  2 in total

1.  Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Ron Dagan
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

2.  Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.

Authors:  Joseph A Lewnard; Louis F Fries; Iksung Cho; Janice Chen; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-14       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.